Clinical TrialsKura's strong position is highlighted by their ongoing updates and upcoming phase 3 trials in 1L fit and unfit AML, supported by FDA permitting use of MRD as a surrogate.
Financial PositionThe company ended the quarter financially strong with $630.7 million in cash, which management believes provides runway into 2027.
PartnershipsAdditional collaboration agreement payments are anticipated from partner Kyowa Kirin, which should support ziftomenib AML program through commercialization in 1L combination settings.